Agilent Technologies
91 Blue Ravine Rd
Folsom
California
95630
United States
Tel: +1 916-985-7888
Website: https://www.agilent.com/about/workingwa/in...
Email: RM@cielotalent.com
About Agilent Technologies
Premier Laboratory Partner for a Better World
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services, and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us.
Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals, or food testing, Agilent provides laboratory solutions to meet their full spectrum of needs. We work closely with customers to help address global trends that impact human health and the environment and to anticipate future scientific needs. Our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management.
Customers trust Agilent for solutions that enable insights...for a better world.
649 articles about Agilent Technologies
-
Agilent Announces New NovoCyte Flow Cytometer System Software for 21 CFR Part 11 Compliance
2/9/2023
Agilent Technologies Inc. (NYSE: A) today announced the release of new NovoExpress software that introduces integrated compliance tools for NovoCyte flow cytometer systems.
-
Agilent to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28
1/30/2023
Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2023 after the stock market closes on Tuesday, Feb. 28.
-
Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test
1/23/2023
Agilent Technologies Inc. (NYSE: A) today announced an agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services.
-
Agilent Included in Just Capital’s 2023 List of Most Just Companies
1/18/2023
Ranking Underscores Agilent’s Strong Performance on Issues of Greatest Importance to Americans Agilent Technologies Inc. is ranked 35 among the top 100 Most JUST companies, the fifth year the company has been included in the annual list by Just Capital and CNBC.
-
Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
1/9/2023
Agilent Technologies Inc. announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients.
-
Agilent Authorizes $2 Billion Share Repurchase Program
1/9/2023
Agilent Technologies Inc. announced that its board of directors has approved a new share repurchase program.
-
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
1/6/2023
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications.
-
Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
1/4/2023
Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.
-
Agilent to Present at Goldman Sachs and J.P. Morgan Healthcare Conferences - December 16, 2022
12/16/2022
Agilent Technologies Inc. announced that CEO Mike McMullen and CFO Bob McMahon will present at the Goldman Sachs Healthcare CEOs Unscripted Conference and the J.P. Morgan Healthcare Conference.
-
Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer
12/13/2022
Agilent Technologies Inc. announced that the U.S. Food and Drug Administration has approved Agilent Resolution ctDx FIRST as a companion diagnostic to identify advanced non-small cell lung cancer patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM.
-
Agilent Again Named to Newsweek’s List of America’s Most Responsible Companies
12/7/2022
Moves up 28 places from 2022 Agilent Technologies Inc. announced the company is ranked 101 in Newsweek’s 2023 list of America’s Most Responsible Companies, up 28 places from 2022.
-
Agilent Opens Customer Experience Center Highlighting Genomics and Diagnostics Solutions
12/5/2022
Agilent Technologies Inc. (NYSE: A) today announced the opening of a new Customer Experience Center (CEC) in Lexington, MA, focused on solutions from Agilent genomics and diagnostics product portfolios.
-
Agilent Attains ‘Angel’ Level Sponsorship with My Green Lab
11/30/2022
Agilent Technologies Inc. (NYSE: A) today announced that it has become the first ‘Angel’ level sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science.
-
Agilent Deploys Next Generation Explosive Detection System at London Heathrow Airport
11/29/2022
Agilent Technologies Inc. announced the deployment of the next generation of alarm resolution technology for checkpoints throughout London Heathrow airport, delivering advanced security and efficiency.
-
Agilent Reports Fourth-Quarter and Fiscal Year 2022 Financial Results
11/21/2022
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.85 billion for the fourth quarter ended Oct. 31, 2022, an increase of 11% compared to the fourth quarter of 2021 and up 17% on a core(1) basis.
-
Agilent to Present at the Evercore ISI HealthCONx Conference
11/16/2022
Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 5th Annual Evercore ISI HealthCONx conference on Wednesday, November 30, at 10:50 a.m. PST.
-
Agilent Announces Cash Dividend of 22.5 Cents Per Share
11/16/2022
Agilent Technologies Inc. announced the company has increased its quarterly dividend to 22.5 cents per share of common stock, reflecting a 7% increase over the previous quarter.
-
Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0
11/14/2022
Agilent Technologies Inc. (NYSE: A) today announced the release of the AssayMAP Bravo Protein Sample Prep Workbench 4.0 software.
-
Agilent to Announce Fourth-Quarter Fiscal Year 2022 Financial Results Nov. 21
11/1/2022
Agilent Technologies Inc. (NYSE: A) today announced it will release financial results for the fourth quarter of fiscal year 2022 after the stock market closes on Monday, Nov. 21.
-
The gene sequencing industry has really taken off in recent years. Here's a look at the top five genome sequencing companies, ranked by revenue.